FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BONIUK MILTON
2. Issuer Name and Ticker or Trading Symbol

NANOVIRICIDES, INC. [ NNVC ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1111 HERMANN DRIVE, UNIT 29E
3. Date of Earliest Transaction (MM/DD/YYYY)

2/21/2017
(Street)

HOUSTON, TX 77004
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share   2/21/2017     M (1)    1746288   A   (2) 2776793   I   Held by Boniuk Interests, Ltd. (   (3)
Common Stock, par value $0.001 per share   2/21/2017     A (4)    153611   A   (4) 1092426   I   Held by the Milton Boniuk IRA   (5)
Common Stock, par value $0.001 per share   5/4/2017     A (6)    149478   A   (6) 1241904   I   Held by the Milton Boniuk IRA   (5)
Common Stock, par value $0.001 per share   7/11/2017     A (7)    120744   A   (7) 1362648   I   Held by the Milton Boniuk IRA   (5)
Common Stock, par value $0.001 per share   5/21/2018     M (8)    5500000   A   (9) 6862648   I   Held by the Milton Boniuk IRA   (5)
Common Stock, par value $0.001 per share                  823428   D   (10)  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
8% Coupon Series B Convertible Debenture   $1.00   (2) 2/21/2017     M   (1)       $2000000   (1)   1/31/2017     (11) Common Stock   1746288   (1) $2000000   (1) 0   I   Held by Boniuk Interests, Ltd.   (3)
10% Coupon Series C Convertible Debenture   $5.25   (9) 5/21/2018     M   (8)       $5000000   (8)   6/30/2018     (11) Common Stock   5500000   (8) $5000000   (8) 0   I   Held by the Milton Boniuk IRA   (5)
Series A Conv Pref Stock, par value $0.001 per share   $0   (12) 5/21/2018     A   (13)    150000         (12)   (11) Common Stock   525000   $0   (13) 337500   I   Held by the Milton Boniuk IRA   (5)

Explanation of Responses:
(1)  Pursuant to the Conversion and Settlement Agreement, dated as of February 8, 2017 (the "Series B Debenture Conversion Agreement"), between the Issuer and Boniuk Interests, Ltd. (the "Partnership"), on February 21, 2017 the Issuer issued to the Partnership 1,746,288 shares of Common Stock in connection with the Issuer's conversion into shares of Common Stock of the Issuer's 8% Coupon Series B Convertible Debenture due January 31, 2017 (the "Series B Debenture"), including the entire $2,000,000 principal amount plus unpaid interest through the stated maturity date.
(2)  The effective price per share of Common Stock issued pursuant to the Series B Debenture Conversion Agreement was approximately $1.15.
(3)  The securities reported in this row are held by the Partnership, a Texas limited partnership. The Reporting Person, as the managing general partner of the Partnership, may be deemed the beneficial owner of such securities for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
(4)  The Issuer issued such shares to the Milton Boniuk IRA (the "IRA") in payment of quarterly interest due on the Issuer's 10% Coupon Series C Convertible Debenture due June 30, 2018 (the "Series C Debenture"), at an effective price of approximately $1.08 per share of Common Stock.
(5)  The securities reported in this row are held by the IRA. The Reporting Person, as the owner and beneficiary of the IRA, may be deemed the beneficial owner of such securities for purposes of Section 16(a) of the Exchange Act.
(6)  The Issuer issued such shares to the IRA in payment of quarterly interest due on the Series C Debenture, at an effective price of approximately $1.11 per share of Common Stock.
(7)  The Issuer issued such shares to the IRA in payment of quarterly interest due on the Series C Debenture, at an effective price of approximately $1.38 per share of Common Stock.
(8)  Pursuant to the Debenture Redemption Agreement, dated as of November 13, 2017 (the "Series C Debenture Redemption Agreement"), between the Issuer and the IRA, on May 21, 2018 the Issuer issued to the IRA 5,500,000 shares of Common Stock in connection with the Issuer's redemption in full of the Series C Debenture, including the entire $5,000,000 principal amount plus unpaid interest of $500,000 through the stated maturity date.
(9)  The effective price per share of Common Stock issued pursuant to the Series C Debenture Redemption Agreement was $1.00.
(10)  The securities reported in this row include 194,857 shares of Common Stock held directly by the Reporting Person and 628,571 shares of Common Stock held jointly by the Reporting Person and his spouse.
(11)  There is no expiration date for the Series B Debenture, the Series C Debenture or the Series A Convertible Preferred Stock.
(12)  Each share of Series A Convertible Preferred Stock is convertible by the holder into 3.5 shares of Common Stock upon a change of control of the Issuer, as defined in the certificate of designation relating to the Series A Convertible Preferred Stock.
(13)  Pursuant to the Series C Debenture Redemption Agreement, the Issuer issued to the IRA 150,000 shares of Series A Convertible Preferred Stock, as consideration for the IRA's waiver of certain rights under the Series C Debenture.

Remarks:
The Reporting Person served as a director of the Issuer from approximately May 28, 2013 until his resignation as a director of the Issuer on July 10, 2018. The Reporting Person currently remains subject to Section 16 of the Exchange Act as the beneficial owner of more than 10 percent of the outstanding Common Stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BONIUK MILTON
1111 HERMANN DRIVE, UNIT 29E
HOUSTON, TX 77004

X


Signatures
/s/ Milton Boniuk 10/11/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more NanoViricides Charts.
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more NanoViricides Charts.